25 related articles for article (PubMed ID: 38443333)
1. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tan TJ; Sammons S; Im YH; She L; Mundy K; Bigelow R; Traina TA; Anders C; Yeong J; Renzulli E; Kim SB; Dent R
Clin Cancer Res; 2024 Apr; 30(7):1240-1247. PubMed ID: 38236575
[TBL] [Abstract][Full Text] [Related]
2. A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.
Harutyunyan L; Manvelyan E; Karapetyan N; Bardakhchyan S; Jilavyan A; Tamamyan G; Avagyan A; Safaryan L; Zohrabyan D; Movsisyan N; Avinyan A; Galoyan A; Sargsyan M; Harutyunyan M; Nersoyan H; Stepanyan A; Galstyan A; Danielyan S; Muradyan A; Jilavyan G
Curr Oncol; 2024 Mar; 31(3):1323-1334. PubMed ID: 38534933
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Lliberos C; Richardson G; Papa A
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785992
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
6. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
[TBL] [Abstract][Full Text] [Related]
7. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y; Kim JW; Penson RT; O'Malley DM; Parkinson C; Roxburgh P; Plummer R; Im SA; Imbimbo M; Ferguson M; Rosengarten O; Steeghs N; Kim MH; Gal-Yam E; Tsoref D; Kim JH; You B; De Jonge M; Lalisang R; Gort E; Bastian S; Meyer K; Feeney L; Baker N; Ah-See ML; Domchek SM; Banerjee S;
Clin Cancer Res; 2024 Jan; 30(1):50-62. PubMed ID: 37939124
[TBL] [Abstract][Full Text] [Related]
8. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G; Floquet A; Tredan O; Carrot A; Langlois-Jacques C; Lopez J; Selle F; Abdeddaim C; Leary A; Dubot-Poitelon C; Fabbro M; Gladieff L; Lamuraglia M
Nat Commun; 2024 Mar; 15(1):1985. PubMed ID: 38443333
[TBL] [Abstract][Full Text] [Related]
10. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]